SCHEMBL24539809

SCHEMBL24539809

c1ccc(N(c2ccccc2)c2ccc(-c3cccc4c5ccc6oc7ccccc7c6c5c5ccccc5c34)cc2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.33
BACE1 P56817 1/20 0.33
TNKS O95271 1/20 0.33
CDC14B O60729 3/20 0.32
CDC14A Q9UNH5 3/20 0.32
PLA2G2A P14555 2/20 0.32
PLA2G4A P47712 2/20 0.32
PLA2G10 O15496 1/20 0.32
MAOA P21397 2/20 0.32
KDM4E B2RXH2 4/20 0.32
ALDH1A1 P00352 4/20 0.32
MAPT P10636 4/20 0.32
HPGD P15428 3/20 0.32
CYP3A4 P08684 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27011726 0.97 PLA2G2A (0.35) ALOX5BACE1TNKSCDC14BCDC14A
SCHEMBL24539820 0.97 PLA2G2A (0.35) ALOX5BACE1TNKSCDC14BCDC14A
SCHEMBL27011759 0.96 PLA2G2A (0.35) ALOX5BACE1TNKSCDC14BCDC14A
SCHEMBL27011777 0.96 PLA2G2A (0.35) ALOX5BACE1TNKSCDC14BCDC14A
SCHEMBL27011874 0.94 TDP1 (0.36) BACE1KDM4EALDH1A1MAPTHPGD
SCHEMBL27012065 0.93 PLA2G2A (0.34) ALOX5BACE1TNKSCDC14BCDC14A
SCHEMBL24539807 0.93 PLA2G2A (0.37) ALOX5TNKSCDC14BCDC14APLA2G2A
SCHEMBL24539812 0.93 PLA2G2A (0.37) ALOX5TNKSCDC14BCDC14APLA2G2A
SCHEMBL27011764 0.93 PLA2G2A (0.37) ALOX5TNKSCDC14BCDC14APLA2G2A
SCHEMBL27011768 0.93 PLA2G2A (0.37) ALOX5TNKSCDC14BCDC14APLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 US disclosed
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 US disclosed
WO-2022131546-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER 엘티소재주식회사 2022-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER CYP1B1, NOTUM, CYP4F11 ALOX5 238/4885BACE1 36/4885TNKS 3194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.